drugset / Trial / NCT04072679
Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase Ib study to evaluate the safety, tolerability and efficacy of Sintilimab combined with IBI305 in patients with advanced hepatocellular carcinoma in China.
Timeline
- Start
- 2018-10-11
- Primary completion
- 2020-03-31
- Completion
- 2020-11-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | — |
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | — |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | — |